Abstracts tagged "Cytokines and macrophage activation syndrome"

Abstract Number: 1895 • 2017 ACR/ARHP Annual Meeting
Serum Interleukin 18 As a Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome and Use of Recombinant Human IL-18 BP in a Patient with Refractory Disease
Shima Yasin¹, Rachel Brown¹, Ndate Fall², Krista Solomon¹, Scott Canna³, Charlotte Girard⁴, Cem Gabay⁵, Eduardo Schiffrin⁶, Andrew Sleight⁶, Alexei A. Grom⁷ and Grant Schulert⁸, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ³NIAMS, National Institutes of Health, Bethesda, MD, ⁴Division of Rheumatology, Department of Internal Medicine Specialties, University Hospital of Geneva, Geneva, Switzerland, ⁵SCQM, Geneva, Switzerland, Geneva, Switzerland, ⁶AB2 Bio, Lausanne, Switzerland, ⁷Division of Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States Minor Outlying Islands, ⁸Pediatric Rheumatology, Division of Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis is an autoinflammatory childhood arthritis with prominent innate immune activity. Macrophage activation syndrome is a severe and potentially fatal complication…
Abstract Number: 74 • 2017 Pediatric Rheumatology Symposium
Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
Esraa M. A. Eloseily^1,2, Peter Weiser¹, Hilary Haines³, Melissa Mannion⁴, Matthew L. Stoll¹, Timothy Beukelman¹, Prescott Atkinson⁵ and Randy Q. Cron¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Pediatrics, Assiut University, Assiut, Egypt, ³Pediatric Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, ⁴Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatric Allergy and Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Familial, or primary, hemophagocytic lymphohistiocytosis (pHLH), is a rare but highly fatal condition due to mutations in lymphocyte cytolytic pathway genes. Secondary HLH (sHLH),…
Abstract Number: 316 • 2014 ACR/ARHP Annual Meeting
Cytokines in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome: Tipping the Balance Between Interleukin-18 and Interferon-Gamma
Karen Put¹, Anneleen Avau¹, Ellen Brisse¹, Tania Mitera¹, Stéphanie Put¹, Paul Proost², Brigitte Bader-Meunier³, Rene Westhovens⁴, Benoît Van den Eynde⁵, Ciriana Orabona⁶, Francesca Fallarino⁶, Lien De Somer⁷, Thomas Tousseyn⁸, Pierre Quartier³, Carine Wouters⁷ and Patrick Matthys¹, ¹University of Leuven, Laboratory of Immunobiology, Rega Institute, Leuven, Belgium, ²University of Leuven, Laboratory of Molecular Immunology, Rega Institute, Leuven, Belgium, ³Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ⁴University of Leuven, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration; Rheumatology, University Hospital Leuven, Leuven, Belgium, ⁵Institut de Duve, Université catholique de Louvain, Brussels, Belgium, ⁶Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy, ⁷University of Leuven, Laboratory of Pediatric Immunology, University Hospital Leuven, Leuven, Belgium, ⁸University of Leuven, Department of Imaging and Pathology, Leuven, Belgium
Background/Purpose To study the role of interferon-gamma (IFN-γ) in the pathogenesis of systemic juvenile idiopathic arthritis (sJIA) and macrophage activation syndrome (MAS) by searching for…
Abstract Number: 954 • 2013 ACR/ARHP Annual Meeting
Correlating The In Vivo Production Of IFNγ To Disease Parameters In TLR9-Induced Macrophage Activation Syndrome (MAS) In Mice
Vanessa Buatois¹, Laurence Chatel¹, Laura Cons¹, Sabrina Lory¹, Maureen Deehan¹, Jennifer Sims², Cristina de Min³, Marie Kosco-Vilbois¹ and Walter Ferlin¹, ¹NovImmune S.A., Geneva, Switzerland, ²Integrated Biologix GmBH, Basel, Switzerland, ³Novimmmune S.A., Plan-Les-Ouates, Geneva, Switzerland
Background/Purpose: Cytokine release is the hallmark feature in mice given repeated injections of the TLR9 agonist, CpG-containing oligodeoxynucleotides (CpG-ODN), resulting in pathology resembling the human…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].